Recruiting
Phase 2

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Sponsor:

Replimune Inc.

Code:

NCT03767348

Conditions

Cancer

Melanoma (Skin)

Mismatch Repair Deficiency

Microsatellite Instability

Non-melanoma Skin Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RP1

nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information